The prognostic value of serum tau in patients with intracerebral hemorrhage.

Clin Biochem

Department of Neurology, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310000, China.

Published: November 2012

Objectives: This study aimed to investigate the relationship between serum tau concentrations and 3-month clinical outcomes in patients with intracerebral hemorrhage.

Design And Methods: Serum tau concentrations of 176 patients were quantified by enzyme-linked immunosorbent assay. The end points were mortality and poor outcome (modified Rankin Scale score>2) after 3 months.

Results: 110 patients (62.5%) had a poor outcome at 3 months. The 3-month mortality rate was 36.4% (64/176). A forward stepwise logistic regression selected serum tau concentration as an independent predictor for 3-month mortality (P=0.002) and poor outcomes (P=0.009) of patients. A receiver operating characteristic curve analysis showed that serum tau concentration predicted 3-month mortality (P=0.001) and poor outcomes (P=0.001) statistically significantly. The area under curve of tau was similar to that of the National Institutes of Health Stroke Scale score for 3-month mortality (P=0.715) and poor outcomes (P=0.315). In a combined logistic-regression model, tau statistically significantly improved the area under curve of the National Institutes of Health Stroke Scale score for the prediction of 3-month poor outcome (P=0.039), but not for the prediction of 3-month mortality (P=0.106).

Conclusions: Serum tau concentration represents a novel biomarker for predicting mortality and poor outcomes at 3 months in patients with intracerebral hemorrhage.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clinbiochem.2012.06.003DOI Listing

Publication Analysis

Top Keywords

serum tau
24
3-month mortality
20
poor outcomes
16
patients intracerebral
12
poor outcome
12
tau concentration
12
tau
8
intracerebral hemorrhage
8
tau concentrations
8
mortality poor
8

Similar Publications

Background: Aggressive angiomyxoma (AAM) is a rare benign mesenchymal tumor known for its aggressive behavior and high recurrence rates, with male cases of AAM being less frequently reported. This study presents a rare case of primary prostatic AAM characterized by a prostatic urethral mass obstructing the bladder outlet, resulting in acute renal dysfunction.

Case Description: The 51-year-old male patient presented with lumbar pain, nausea, frequent urination, urgency, and incomplete urination.

View Article and Find Full Text PDF

Background: Little is known about confounding factors influencing Alzheimer's disease (AD) blood biomarker concentrations.

Objective: The objective of this systematic review was to explore the available evidence for the influences of ethnicity and race on AD blood biomarker concentrations.

Methods: We conducted a comprehensive systematic search in PubMed and Web of Science databases spanning from inception until 15 June 2023.

View Article and Find Full Text PDF

Tungsten disulphide nanosheet modulated fluorescent gold nanocluster immunoprobe for the detection of tau peptide: Alzheimer's disease biomarker.

Anal Methods

January 2025

Department of Chemistry, School of Physical and Mathematical Science, Research Centre, University of Kerala, Kariavattom Campus, Thiruvananthapuram, Kerala, 695581, India.

The neuronal tau peptide serves as a key biomarker for neurodegenerative diseases, specifically, Alzheimer's disease, a condition that currently has no cure or definitive diagnosis. The methodology to noninvasively detect tau levels from body fluids remains a major hurdle for a rapid and simple diagnostic approach. Thus, developing new detection methods for sensing tau protein levels is crucial.

View Article and Find Full Text PDF

Alzheimer's disease (AD) is the most commonly occurring brain disorder, characterized by the accumulation of amyloid-β (Aβ) and tau, subsequently leading to neurocognitive decline. 3-Amino-1-propanesulfonic acid (TPS) and its prodrug, currently under clinical trial III, serve as promising therapeutic agents targeting Aβ pathology by specifically preventing monomer-to-oligomer formation. Inspired by the potency of TPS prodrug, we hypothesized that conjugating TPS with human serum albumin (HSA) could enhance brain delivery and synergistically inhibit Aβ aggregation in mild to moderate AD.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!